Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-85.

Article  CAS  PubMed  Google Scholar 

Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.

Nedkoff L, Briffa T, Zemedikun D, Herrington S, Wright FL. Global trends in atherosclerotic cardiovascular disease. Clin Ther. 2023;45(11):1087–91.

Article  PubMed  Google Scholar 

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702.

CAS  PubMed  Google Scholar 

Ionescu VA, Gheorghe G, Bacalbasa N, Diaconu CC. Metabolic dysfunction-associated steatotic liver disease: pathogenetic links to cardiovascular risk. Biomolecules. 2025. https://doi.org/10.3390/biom15020163.

Article  PubMed  PubMed Central  Google Scholar 

Castillo-Núñez Y, Almeda-Valdes P, González-Gálvez G, Arechavaleta-Granell MDR. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis. Curr Diab Rep. 2024;24(7):158–66.

Article  PubMed  Google Scholar 

Zisis M, Chondrogianni ME, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, et al. Linking cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD): the role of cardiometabolic drugs in MASLD treatment. Biomolecules. 2025. https://doi.org/10.3390/biom15030324.

Article  PubMed  PubMed Central  Google Scholar 

Basil B, Myke-Mbata BK, Eze OE, Akubue AU. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol. 2024;10(1):39.

Article  PubMed  PubMed Central  Google Scholar 

Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28–34.

Article  PubMed  Google Scholar 

Cheng CK, Huang Y. The gut-cardiovascular connection: new era for cardiovascular therapy. Med Rev. 2021;1(1):23–46.

Article  Google Scholar 

Yaghmaei H, Taromiha A, Nojoumi SA, Soltanipur M, Shahshenas S, Rezaei M, et al. Role of Gut-liver axis in non-alcoholic fatty liver disease. Iran Biomed J. 2025;29(1 & 2):1–8.

PubMed  PubMed Central  Google Scholar 

Maiuolo J, Carresi C, Gliozzi M, Mollace R, Scarano F, Scicchitano M, et al. The contribution of gut microbiota and endothelial dysfunction in the development of arterial hypertension in animal models and in humans. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23073698.

Article  PubMed  PubMed Central  Google Scholar 

Li Z, Li Z, Cao D, Hu Y. Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world. J Hepatol. 2025;82(1):e29–31.

Article  Google Scholar 

Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13.

Article  PubMed  Google Scholar 

De Filippo O, Di Pietro G, Nebiolo M, Ribaldone DG, Gatti M, Bruno F, et al. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: a meta-analysis. Eur J Clin Invest. 2024;54(9):e14188.

Article  CAS  PubMed  Google Scholar 

Kapuria D, Takyar VK, Etzion O, Surana P, O’Keefe JH, Koh C. Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis. Hepatol Commun. 2018;2(8):877–87.

Article  Google Scholar 

Nso N, Bookani KR, Trimingham M, Orji R, Njei B, Balasubramanian SS, et al. Liver fibrosis and cardiovascular events. South Med J. 2025;118(1):19–25.

Article  CAS  PubMed  Google Scholar 

Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138–43.

Article  CAS  PubMed  Google Scholar 

Li T, Zhao J, Cao H, Han X, Lu Y, Jiang F, et al. Dietary patterns in the progression of metabolic dysfunction-associated fatty liver disease to advanced liver disease: a prospective cohort study. Am J Clin Nutr. 2024;120(3):518–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nam H, Yoo JJ, Cho Y, Kang SH, Ahn SB, Lee HW, et al. Effect of exercise-based interventions in nonalcoholic fatty liver disease: a systematic review with meta-analysis. Dig Liver Dis. 2023;55(9):1178–86.

Article  PubMed  Google Scholar 

Bernhard J, Galli L, Speidl WS, Krychtiuk KA. Cardiovascular risk reduction in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. Curr Cardiol Rep. 2025;27(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916-22.

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-90

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-96

Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919-28

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021;385(17):1547-58

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542.

Brown JD, Buscemi J, Milsom V, Malcolm R, O’Neil PM. Effects on cardiovascular risk factors of weight losses limited to 5–10. Transl Behav Med. 2016;6(3):339–46.

Article  PubMed  Google Scholar 

Moolla A, Poolman T, Othonos N, Dong J, Smith K, Cornfield T, et al. Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD. JHEP Reports. 2025;7(5):101363.

Article  PubMed  PubMed Central  Google Scholar 

Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al. Role of MASLD in CVD: a review of emerging treatment options. Diabetes Res Clin Pract. 2024;217:111891.

Article  CAS  PubMed  Google Scholar 

Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2024;22(8):1565–74.

Article  CAS  PubMed  Google Scholar 

Choi R, Vemuri J, Poloju A, Raj R, Mehta A, Asgharpour A, et al. Current and emerging treatments for metabolic associated steatotic liver disease and diabetes: a narrative review. Endocrines. 2025;6(2):27.

Article  CAS  Google Scholar 

Keam SJ. Resmetirom: first approval. Drugs. 2024;84(6):729–35.

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47.

Article  PubMed  Google Scholar 

Chen MJ, Chen Y, Lin JQ, Hu R, Liu D, Chen JY, et al. Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease. Front Nutr. 2024;11:1421386.

Article  PubMed  Google Scholar 

Kim RG, Ballantyne A, Conroy MB, Price JC, Inadomi JM. Screening for social determinants of health among populations at risk for MASLD: a scoping review. Front Public Health. 2024;12:1332870.

Article  PubMed  PubMed Central  Google Scholar